High-throughput gene expression profiles have allowed discovery of potential biomarkers 9 enabling early diagnosis, prognosis and developing individualized treatment. However, it 10 remains a challenge to identify a set of reliable and reproducible biomarkers across vari-11 ous gene expression platforms and laboratories for single sample diagnosis and prognosis. 12 We address this need with our Data-Driven Reference (DDR) approach, which employs sta-13 bly expressed housekeeping genes as references to eliminate platform-specific biases and 14 non-biological variabilities. Our method identifies biomarkers with "built-in" features, and 15 these features can be interpreted consistently regardless of profiling technology, which en-16 able classification of single-sample independent of platforms. Validation with RNA-seq data 17 of blood platelets shows that DDR achieves the superior performance in classification of six 18 different tumor types as well as molecular target statuses (such as MET or HER2-positive, 19 1 and mutant KRAS, EGFR or PIK3CA) with smaller sets of biomarkers. We demonstrate on the 20 three microarray datasets that our method is capable of identifying robust biomarkers for 21 subgrouping medulloblastoma samples with data perturbation due to different microarray 22 platforms. In addition to identifying the majority of subgroup-specific biomarkers in Code- 23 Set of nanoString, some potential new biomarkers for subgrouping medulloblastoma were 24 detected by our method. Our results show that the DDR method contributes significantly to 25 single-sample classification of disease and shed light on personalized medicine. 26 Background 27 Identification of reliable and reproducible biomarkers can contribute to reveal patterns of dis-28 ease heterogeneity. Recent advances in High-throughput sequencing (HTS) technology, such 29
: Expression levels of five data-driven reference genes from TCGA BRCA RNA-Seq samples and tiers classified based on reference genes (top). The contingency table of ESR1 expression based on expression levels of reference genes (bottom). ray expression data. Four reference genes ( Fig. S3 ) were selected from expression microarray 83 data (Accession: GSE62872), so that the differences between expressions of two consecutive 84 reference genes were around 2. Then, the DEGs were identified by DDR and ranked by adjusted To assess DDR's ability to detect DEGs, we compared it with the tools widely used in differen-88 tial expression analysis in various platforms. The Fisher's exact test is a nonparametric test in 89 Figure 2: Precision and recall of methods in two TCGA RNA-Seq datasets: precision (A) and recall (C) in BRCA data and precision (D) and recall (E) in LUAD data. The false discovery rate (FDR) on the basis of mock comparisons generated using two datasets: 116 TNBC samples from TCGA-BRCA dataset (C) and 59 normal samples from LUAD (F). (Table 1A) , was retained and their tier information (Supplementary Excel V) served as input to S6B, it can be seen that SVM achieved slightly better performance (Accuracy: 92%) though the 154 other classifiers performed as well on classification task. Most of non-TNBC breast cancer sam-155 ples were correctly predicted (Accuracy: 95%), whereas the proportion of mis-assigned TNBC 156 samples was a little high (Table 1A) . To evaluate the capacity of six selected signature genes Excel V) based on reference genes from GSE27447 dataset as input to SVM classifier trained 162 on TCGA-BRCA dataset, 4/5 (80%) and 12/14 (86%) were classified correctly to TNBC and non-163 TNBC, respectively (Table 1B) . These examples demonstrate DDR's ability to identify robust 164 biomarkers for cross-platform classification of single patient.
165
To examine subgrouping ability of up-regulated genes, two up-regulated (BCL11A, B3GNT5) 166 genes from top 20 ranked genes were used as signature to classify TCGA-BRCA samples, which 167 yielded an accuracy of 91%, and a recall of 81% (Table 1C ). Subsequent validation using GSE27447 168 microarray dataset yield an accuracy of 95% and a recall of 90% when using SVM classifier for pan-cancer classification. The tiered categorizations of 596 genes were used as input to 193 multi-class One-versus-One (OvO) SVM classifier to yield overall accuracy of 72% (Table 2A) misclassified to G4 subgroup (7/27), and two G4 cases were misclassified to G3 group ( G3 and G4, respectively (Fig. S8A ). Using SVM classifier, we correctly classified G3 and G4 sub-241 groups with average 96% accuracy using MCCV (Table S5A ). Subsequent validation using six 242 signature genes and SVM classifier trained on GSE37418 dataset, yielded accuracies of 90% and 243 94% in GSE21140 and GSE37382 datasets, respectively, when subgrouping G3 and G4 ( Fig. S8B   244 and S8C). More G3 cases were correctly assigned in both validation datasets compared with 245 predictions above (Table S5B and S5C). It is worthwhile to note that the expression level of EN2, 246 which improved G3/G4 classification performance, has been reported to alter glioma cell mor-247 phology 46 .
248

Discussion
249
In the past decades, a wide variety of methods have been developed to identify biomarkers (fea- = 0 and r (k) n+1 = ∞ (Fig. 1) .
378
Identification of Discriminant Genes
379
A C ×T contingency table was created for each gene, here C is the number of conditions and T is 380 the number of tiers, to display the numbers of samples from a particular condition in which that 381 gene was assigned to a particular tier ( Fig. 1) . Then, Fisher's exact tests (FETs) were performed 382 for the contingency tables to assess whether the expression level of the gene is independent or 383 correlated with conditions or phenotypes. The resulting p-values were adjusted to account for 384 multiple tests using the p.adjust function in R (method = 'fdr'). In addition to adjusted p-values, 385 we defined expression distance (ED) for each gene to describe a quantity change of the gene 386 expression between conditions. The ED can be used to select up-and down-regulated genes. To evaluate the false discovery rate of different methods, we randomly assigned the equal sizes 400 of samples from the same condition without replacement into two groups and the procedure 401 was repeated 10 times. All samples were from the same condition, which means that there 402 should not be any real DEGs, so DEGs identified from simulated datasets arise by chance alone.
403
The false discovery rate was defined as ratio of the number of identified DEGs from simulated 404 dataset to the number of identified DEGs by comparing two conditions from complete dataset. 405 We compared the overlaps of the identified DEGs between the methods by Szymkiewicz-Simpson 406 overlap coefficient. Table S3 . 
